The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

ROR1 targeting with the antibody drug-conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models

(2021) Tiziana Vaisitti et al.   BLOOD

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody

(2019) Suping Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway

(2019) Qian Zhang et al.   JOURNAL OF IMMUNOLOGY

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

(2019) Tiziana Vaisitti et al.   BLOOD

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

(2018) Michael Y. Choi et al.   Cell Stem Cell

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

(2016) B. Cui et al.   BLOOD

Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

(2016) Ashwini Balakrishnan et al.   CLINICAL CANCER RESEARCH

The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers

(2012) Suping Zhang et al.   AMERICAN JOURNAL OF PATHOLOGY